Liver X receptor α mediates hepatic triglyceride accumulation through upregulation of G0/G1 Switch Gene 2 expression

Bradlee L. Heckmann,1,2 Xiaodong Zhang,1,2 Alicia M. Saarinen,1,2 Gabriele Schoiswohl,4 Erin E. Kershaw,4 Rudolf Zechner,5 and Jun Liu1,2,6

1Department of Biochemistry and Molecular Biology, 2HEALth Program, Mayo Clinic in Arizona, Scottsdale, Arizona, USA. 3Mayo Graduate School, Rochester, Minnesota, USA. 4Division of Endocrinology, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. 5Institute of Molecular Biosciences, University of Graz, Graz, Austria. 6Division of Endocrinology, Mayo Clinic in Arizona, Scottsdale, Arizona, USA.

Introduction

The synthesis and hydrolysis of intrahepatic lipids are critical processes for the maintenance of systemic energy homeostasis (1–3). During the fed state, insulin stimulates storage of dietary fatty acids (FAs) in the form of triglycerides (TGs) in white adipose tissue (WAT). In contrast, fasting induces the efflux of free FAs from WAT and their subsequent uptake in nonadipose tissues, including liver. Free FAs taken up by hepatocytes can either be oxidized in mitochondria or reesterified into TGs, which are subsequently packaged and resecreted as very low-density lipoprotein (VLDL) particles. During fasting, the rate of hepatic FA uptake frequently exceeds the net rate of FA utilization, leading to increased TG synthesis and storage within intracellular lipid droplets (4–6).

Studies by our laboratory and others have identified G0/G1 Switch Gene 2 (G0S2) as a selective endogenous inhibitor of adipose triglyceride lipase (ATGL) (7–10), the rate-limiting TG hydrolase in various tissues including adipose tissue, cardiac muscle, and liver (11–16). During fasting, G0S2 is upregulated in the liver, where it acts critically to coordinate hepatic substrate utilization by decreasing the amount of available FAs and increasing the rates of glycogen breakdown (17–19). Specifically, global KO of G0S2 in mice leads to an impaired hepatic fasting response in terms of TG accumulation and glycogen depletion, along with enhanced adipose lipolysis (20–22). Mice with liver-specific G0S2 ablation exhibit increased hepatic ATGL-mediated TG hydrolysis and FA oxidation, along with decreased TG storage upon fasting (20). Despite the recent evidence that hepatic G0S2 expression is induced during fasting downstream of adipose lipolysis, as seen in mice lacking the lipase coactivator comparative gene identification-58 (CGI-58-ATko) (23), the identity of the responsible transcription factor in the liver is still unknown.

Conflict of interest: The authors have declared that no conflict of interest exists.

Submitted: May 23, 2016
Accepted: January 9, 2017
Published: February 23, 2017

Reference information:
The liver X receptor family of transcription factors (LXRα and LXRβ) is known to play a central role in the regulation of cholesterol homeostasis and lipid synthesis (24, 25). LXRα control hepatic lipogenesis mainly through mediating the expression of SREBP-1c and its target genes for FA synthesis, including acetyl-CoA carboxylase (ACC), fatty acid synthase (FAS), and stearoyl-CoA desaturase-1 (SCD1) (26–29). Accordingly, LXRαβ double KO mice are characterized by markedly reduced hepatic FA synthesis and incorporation of FA into phospholipids and TGs (30, 31). Interestingly, deletion of LXRα alone also hampers the hepatic TG accumulation and adaptive response to fasting (32), suggesting a regulatory role of LXRα during the influx of adipose-derived FAs. Additionally, synthetic LXR agonists, albeit eliciting antiatherogenic activity via increasing tissue cholesterol efflux and reverse cholesterol trafficking through HDL, are considered undesirable as therapeutic agents due to their detrimental effects of causing hepatic steatosis and hypertriglyceridemia. Genetic studies have defined hepatic LXRα as the predominant subtype required for agonist-induced lipogenesis and formation of steatotic liver (33–35). As hepatic TG accumulation during fasting and in response to LXR agonism both require LXRα, the question arises as to whether a convergent mechanism exists that promotes the deposition of FAs from different sources, adipose-derived versus endogenously generated, as exists for TGs in the liver.

In the present study, we have obtained evidence that hepatic G0S2 is a direct LXRα target gene during fasting and in response to pharmacological agonism of LXR. Consistent with this observation, we have discovered that the effect of LXR activation on liver TG content is mediated through enhanced G0S2 expression.

### Results

**Hepatic expression of G0S2 is upregulated by adipose-derived FAs.** In WT mice, fasting increased hepatic mRNA expression of G0S2 by 8.3-fold and ATGL by 2.3-fold (Figure 1A), indicating a relatively greater effect on G0S2. To determine the contribution of adipocyte lipolysis to the fasting-induced upregulation in liver, we next compared their expression in adipocyte-specific ATGL KO (AAKO) mice that have previously been shown to have severely restricted adipocyte lipolysis (36). In the fasted AAKO mice, mRNA expression of G0S2 was 9.1-fold lower and ATGL was 6.58-fold higher than in the WT mice (Figure 1B). These data suggest that, during fasting, increased hepatic expression of G0S2 but not ATGL is dependent on adipose lipolysis, agreeing with what was recently observed in CGI-58-ATko animals (23).

To ascertain whether adipose lipolysis was directly responsible for activating G0S2 expression in hepatocytes, we cultured mouse primary hepatocytes in conditioned media collected from WT and ATGL –/– (ATGL KO) fat explants. The fat explants were pretreated with either vehicle alone or a β3 receptor agonist CL316243 (CL) to stimulate adipocyte lipolysis. As shown in Figure 1C, expression of G0S2 in the primary hepatocytes was increased by 8.5-fold when cultured in the media derived from CL- versus vehicle-treated WT fat explants. However, the effect of CL stimulation was largely abolished with the media derived from ATGL KO explants (Figure 1C). In comparison, no increase of ATGL expression was observed in the hepatocytes under all conditions. These data confirm that the output of stimulated adipose lipolysis directly drives hepatic expression of G0S2. Moreover, gas chromatographic analysis identified linoleic acid (18:2), oleic acid (18:1), palmitic acid (16:0), and palmitoleic acid (16:1) as the major FA species released from fat explants upon CL stimulation (Figure 1D). Interestingly, treatment with linoleic acid (18:2) or oleic acid (18:1) individually at concentrations consistent with the quantities released from the explants upon CL stimulation significantly increased expression of G0S2 in the primary hepatocytes (Figure 1E). The expression of ATGL was unaffected by individual FA treatment. Additionally, neither G0S2 nor ATGL was changed by treatment with glycerol (Supplemental Figure 1; supplemental material available online with this article; https://doi.org/10.1172/jci.insight.88735DS1), the other lipolytic product released from adipose tissue. These results demonstrate a direct effect of adipose-derived unsaturated FAs to upregulate G0S2 in hepatocytes.

**Hepatic G0S2 expression in response to adipose lipolytic stimulation is dependent on LXRα but not PPARα.** Since the phenotypes exhibited by LXRα-deficient mice during fasting are closely reminiscent of those caused by G0S2 ablation (20, 32), we asked whether increased hepatic G0S2 expression in response to adipose-derived FAs would be related to LXRα. Using qPCR and immunoblotting, we analyzed G0S2 expression in liver tissue isolated from WT and LXRα–/– (LXR KO) mice. Compared with ad libitum feeding, fasting caused a robust increase in the hepatic G0S2 mRNA and protein levels in the WT animals (Figure 2, A and B). Expression of LXRα and 2 of its target genes ABCG5 and ABCA1 were also modestly but significantly increased upon fasting, while the expression of SREBP-1c was decreased. Strikingly, the induction of G0S2 along with ABCG5
and ABCA1 in response to fasting was largely lost in the LXR KO mice (Figure 2, A and B). Hepatic ATGL expression, on the other hand, was increased during fasting regardless of the presence of LXRα (Figure 2, A and B). Similarly, acute stimulation of adipose lipolysis by CL injection increased hepatic G0S2 expression markedly in the WT mice (Figure 2, C and D). However, the LXRα expression was unaffected by CL. The induction of G0S2 expression was likewise abolished in the LXR KO mice. In comparison, ATGL expression exhibited a modest increase similarly in WT and LXR KO mice following CL injection (Figure 2, C and D).

Taken together, these data indicate an LXRα-dependent expression of G0S2 in the liver in response to both fasting- and CL-stimulated adipose lipolysis. Moreover, treatment with individual FAs failed to induce G0S2 expression in LXR KO primary hepatocytes (Figure 1E), confirming that the effect of adipose-derived FAs is mediated through LXRα. Furthermore, LXRα is known to function in a heterodimer with RXR, a FA-responsive transcription factor. Interestingly, treatment of WT mice with a RXR antagonist HX531 also profoundly reduced hepatic expression of G0S2 mRNA and protein upon fasting or CL stimulation (Figure 2, E–H). These results clearly demonstrate that PPARα is not directly involved in mediating the induction of hepatic G0S2 expression.

The heterodimeric transcription factor PPARα/RXR plays a critical role in mediating fasting-induced adaptive energy response and hepatic FA oxidation. A previous study has shown a differential expression of G0S2 in the liver of PPARα−/− mice (37). However, treatment of mouse primary hepatocytes with a PPARα agonist Wy14643 elicited no effect on G0S2 transcription (Figure 3A), while causing a considerable increase in the expression of PPARα target genes, including AcadM, CPT1α, and AcotI. In addition, injection of mice with a PPARα antagonist GW6471, though decreasing expression of PPARα, AcadM, CPT1α, and AcotI (Figure 3B), failed to inhibit fasting-induced expression of G0S2 mRNA and protein in liver (Figure 3, B and C). These results clearly demonstrate that PPARα is not directly involved in mediating the induction of hepatic G0S2 expression.

**Figure 1. Hepatic G0S2 expression occurs in response to adipose-derived fatty acids.** (A) qPCR analysis of hepatic G0S2 and ATGL mRNA expression in 14-week-old male WT mice either fed or fasted for 16 hours. (B) qPCR analysis of hepatic G0S2 and ATGL mRNA expression in 24-week-old male WT and adipose-specific ATGL KO mice (AAKO) mice fasted for 12 hours. (C) WT primary hepatocytes were cultured in adipose explant media as shown. qPCR analysis of G0S2 and ATGL expression in response to coculture in the presence or absence of lipolytically stimulated adipose explants was determined. (D) Adipose tissue isolated from 12-week-old female WT mice was explant cultured and lipolytically stimulated with CL316243 (CL). Media was collected, and fatty acid species released in response to lipolytic activation, along with glycerol released, were profiled and quantified, along with glycerol. (E) Major lipolytically released fatty acid species were individually conjugated to BSA at molar concentrations consistent with those released from adipose explants upon lipolytic stimulation and used to treat WT and LXRα KO primary hepatocytes. Concentrations are as follows: C16:0 = 0.25 mM, C16:1 = 0.16 mM, C18:1 = 0.5 mM, and C18:2 = 0.72 5 mM. qPCR analysis of G0S2 and ATGL expression in response to fatty acid treatment is shown in panel E. (For mice n = 7; for cells n = 3 for qPCR performed in triplicate; *P < 0.05, **P < 0.01, ***P < 0.001, Student’s t test.)
Figure 2. LXRα and RXRα are required for hepatic G0S2 expression in response to fasting and acute stimulation of adipose lipolysis. For panels A and B, 12-week-old female WT and LXRα KO mice were fasted for 16 hours. (A) qPCR analysis of G0S2, ATGL, LXRα, and LXRα target genes in liver. (B) Immunoblot analysis of G0S2 and ATGL expression in liver from 16-hour fasted WT and LXRα KO mice. For panels C and D, 14-week-old female WT and LXRα KO mice were injected with 0.1 mg/kg CL316243 for 1 hour. (C) qPCR analysis of hepatic G0S2, ATGL, LXRα, and LXRα target genes in response to CL injection. (D) Immunoblot analysis of G0S2 and ATGL expression in liver following acute CL injection in WT and LXRα KO mice. For panels E and F, 14-week-old female WT mice were injected with vehicle or HX531 and then fasted for 16 hours. (E) qPCR analysis of hepatic G0S2 and ATGL expression. (F) Immunoblot analysis of G0S2 and ATGL expression in fasted liver. For panels G and H, 15-week-old female WT mice were injected with CL316243 as described above in the presence or absence of HX531. (G) qPCR analysis of G0S2 and ATGL from liver. (H) Immunoblot analysis for hepatic G0S2 and ATGL in CL/HX531 mice. Box-and-whisker plots depict median (line within box), 25th percentile and 75th percentile (bottom and top borders), and range of minimum to maximum values (whiskers; n = 7 [A and C], n = 5 [E and G] for qPCR performed in triplicate; *P < 0.05, **P < 0.01, ***P < 0.001, Student’s t test).
LXRα mediates hepatic G0S2 expression in response to chemical agonism. To directly evaluate the effect of LXR activation on G0S2 expression, we injected WT mice with either T0901317 (T09) or GW3965, 2 synthetic LXR agonists. Upon LXR activation by T09, hepatic G0S2 mRNA expression was increased by over 7-fold, markedly exceeding that of known LXR target genes, including ABCG5, ABCG8, and SREBP1c (Figure 4A). Similar effects were observed with GW3965 injection (Supplemental Figure 2). Cotreatment of mice with either LXR antagonist GSK2033 or RXR antagonist HX531 significantly reduced the mRNA expression of G0S2 and other LXR targets induced by T09 (Figure 4A), again demonstrating the involvement of the LXR/RXR heterodimer. To establish that increased G0S2 expression is caused by transcriptional activation and not due to enhanced mRNA stability, we took advantage of a unique feature of our G0S2–/– (G0S2 KO) mice that have a LacZ reporter placed under the control of the endogenous G0S2 promoter (20). As indicated by β-galactosidase staining of liver sections from these mice, G0S2 transcription was robustly activated by LXR agonism (Figure 4B). More importantly, T09 injection failed to induce hepatic mRNA expression of G0S2, ABCG5, ABCG8, ABCA1, and SREBP-1c in LXR KO mice (Figure 4C). In accordance with the gene transcription, the hepatic G0S2 protein levels also increased in the WT but not LXR KO mice in response to T09 (Figure 4D). In contrast to fasting and CL stimulation, T09 did not affect ATGL expression in the liver, regardless of LXRα (Figure 4, C and D). Together, these results demonstrate the LXRα-dependent nature of G0S2 regulation, as well as argue against the regulation of ATGL by LXRα. This differential regulation of G0S2 and ATGL by LXRα would be expected to alter the molar ratio of the enzyme and its inhibitor in hepatocytes, thereby affecting hepatic lipolysis.

LXRα mediates hepatic G0S2 transcription via direct promoter binding. A nuclear hormone receptor binding site (NHR) scan predicted that a putative LXR response element (LXRE) containing a direct repeat 4-like motif (DR4) is located ~2 kb upstream of the transcriptional start codon of the human, rat, and mouse G0S2 genes (Figure 5A). To determine whether LXRα directly binds to this DR4 motif to mediate transcriptional activation in vivo, we performed ChIP assays on liver samples collected from fed and fasted mice. Relative to ad libitum feeding, a 16-hour fast induced an over 5-fold enrichment of LXRα at the putative LXRE sequence of the G0S2 promoter, while LXRα binding to the known LXRE sites of SREBP1c and ChREBP was drastically reduced upon fasting (Figure 5B). In comparison, LXR activation by T09 caused an over 15-fold enrichment of LXRα at the G0S2 LXRE (Figure 5C). By contrast, no LXRα binding was detected in the 5′ and 3′ regions flanking the putative G0S2 LXRE (Figure 5, B and C). Interestingly, T09 activation...
RESEARCH ARTICLE

promoted enrichment of LXRβ at the LXRE sites of SREBP1c and ChREBP (Figure 5D). Though a modest basal interaction was observed, the enrichment of LXRβ at the G0S2 LXRE was not further enhanced by T09 (Figure 5D). Under all 3 conditions, no significant binding signal was detected when nonspecific control IgG was used (Figure 5, B–D).

To ascertain the binding between the G0S2 LXRE sequence and LXRα/RXR heterodimer, we performed an EMSA using in vitro translated proteins. As shown in Figure 5E, addition of LXRα and RXRα together but not individually produced a shift complex with a biotin-labeled oligonucleotide spanning the LXRE of G0S2. An excess of unlabeled G0S2 LXRE was able to compete for complex formation, confirming the specific binding of LXRα/RXRα to G0S2 LXRE. Binding between the G0S2 LXRE and LXRβ/RXRα did also occur but at a slightly lower affinity (Figure 5E).

To test if LXRα binding to the G0S2 promoter could functionally drive transcription, we constructed pGL4 luciferase reporter plasmids with varying lengths of the murine G0S2 promoter fragments encompassing the LXRE/DR4 motif (Figure 5F). When coexpressed with LXRα and RXRα, both the long (−3,010 to −10) and the short (−2,283 to −1,783) promoter constructs gave rise to significant basal luciferase activity, which was further augmented upon the addition of T09 (Figure 5G). When the DR4 motif is specifically deleted from the short promoter fragment (−2,283 ΔDR4 −1783), there was an approximate 90% reduction in the luciferase activity detected under both basal and T09-stimulated conditions (Figure 5G). Moreover,
Figure 5. LXRe regulates G0S2 expression through direct promoter binding. (A) Sequence alignment of the putative DR4/LXRE identified in the proximal G0S2 promoter across species. Twelve-week-old female WT mice were either fasted for 16 hours or injected with vehicle or T0901317 as described previously. Hepatic lysate was then subjected to ChIP. (B) qPCR analysis of LXRe-specific ChIP chromatin from fed and fasted mice. (C) qPCR analysis of LXRe-specific ChIP chromatin from T09-injected mice. (D) qPCR analysis of LXRe-specific ChIP chromatin from T09-injected mice. For panels B-D, primer
treatment with linoleic acid was also able to significantly induce the luciferase activity in cells transfected with LXRα, RXRα, and the short G0S2 promoter fragment (−2,283 to −1,783) (Figure 5H), an effect that could be largely abolished by the RXR antagonist HX531. On the other hand, neither linoleic acid nor oleic acid affected the ability of a chimeric protein consisting of the ligand-binding domain of LXRα fused to the DNA-binding domain of Gal4 (LXRα-LBD/Gal4-DBD) to drive a Gal4-responsive luciferase reporter in the absence of RXR (Supplemental Figure 3). Together, these data indicate that the DR4 motif identified in the G0S2 promoter is a bona fide LXR that confers LXRα responsiveness, and the effect of unsaturated FAs on G0S2 promoter activity is likely mediated through RXR but not LXRα of the LXRα/RXR dimer.

**G0S2 is essential for fasting-induced hepatic TG accumulation and glycogen depletion downstream of LXRα.** Since loss of LXRα leads to decreases in both hepatic TG content and G0S2 expression during fasting, we tested whether restoring G0S2 expression would be sufficient to enhance TG accumulation in the absence of LXRα. To this end, we injected fasted WT and LXR KO mice with a recombinant adenovirus encoding mouse G0S2 (Ad-G0S2) under the control of a CMV promoter. Compared with that of a control null virus (Ad-Null), injection of Ad-G0S2 increased the hepatic G0S2 protein levels in the WT and LXR KO mice to comparable levels (Figure 6A). In Ad-Null–injected animals, LXRα ablation led to a pronounced reduction in the fasting hepatic TG content (Figure 6B). Ectopic expression mediated by Ad-G0S2 increased the TG content in the LXR KO mice by about 3-fold, though not to the levels observed in the WT animals (Figure 6B). These results suggest that, while multiple LXRα-dependent factors contribute to hepatic TG accumulation during fasting, G0S2 is a key player in the process since restoring G0S2 expression alone in the absence of LXRα is sufficient to prominently enhance hepatic TG levels.

We also compared the changes in the adaptive energy response in fasted WT and LXR KO mice with or without Ad-G0S2 expression. To determine whether altered FA oxidation contributes to the changes in hepatic TG content, we measured the plasma levels of the ketone body 3-hydroxybutyrate (3-HB). In Ad-null–injected mice, LXRα ablation increased the fasting plasma levels of 3-HB by 25% (Figure 6C). Interestingly, Ad-G0S2 expression caused a 29% and 42% reduction in the plasma 3-HB levels in the WT and LXR KO mice, respectively, resulting in no significant difference between the 2 genotypes (Figure 6C).

In accordance with the previous observation, LXRα ablation caused a pronounced delay in the fasting-induced hepatic glycogen depletion (32), which was largely reversed with Ad-G0S2 expression (Figure 6D). Therefore, restoration of hepatic G0S2 expression in the LXR KO mice is sufficient to reverse the impaired response to fasting in terms of hepatic TG accumulation, FA oxidation, and glycogen depletion. In contrast, global energy and cholesterol metabolism appeared unaffected by LXRα or G0S2 since no changes were observed with plasma levels of glucose, free FA, and TG, as well as hepatic or plasma cholesterol levels in mice of all 4 groups (Figure 6E and Table 1).

**G0S2 ablation prevents hepatic steatosis and hypertriglyceridemia induced by LXR agonism.** To explore a possible role of G0S2 in the steatotic development induced by LXR activation, we first examined hepatic TG content in WT and G0S2 KO mice injected with T09. In the WT mice, T09 increased the fed liver and plasma TG content by 212% and 54%, respectively (Figure 7, A and C). However, these effects were completely absent in the G0S2−/− animals (Figure 7, A and C). Histological evaluation of liver specimens also revealed a lack of increased fat vacuoles in G0S2−/− mice (Figure 7B). G0S2 ablation also led to increased plasma 3-HB levels in both vehicle- and T09-treated mice, indicating an increased hepatic FA oxidation (Supplemental Figure 4A). In addition, no significant changes were observed with plasma free FA in both groups (Supplemental Figure 4, B and C), suggesting that, regardless of G0S2, T09 treatment elicits no impact on adipose lipolysis.

Since LXR activation promotes cholesterol efflux from tissues and reverse cholesterol trafficking through HDL, we also evaluated the effects of G0S2 deletion on hepatic and plasma cholesterol profiles. In the WT mice, T09 treatment resulted in a 35% decrease of total hepatic cholesterol (Figure 7D), a 31% increase of total plasma cholesterol (Figure 7E), and a 36% increase of plasma HDL levels (Figure 7F). Interestingly,
G0S2 deficiency elicited no impact on any of these T09-induced effects (Figure 7, C–G). Importantly, loss of G0S2 also did not affect the upregulation of established LXR target genes such as ABCG5, ABCG8, ABCA1, SREBP1c, and FAS by T09 (Figure 7H). The results suggest that the absence of G0S2 leads to reduced hepatic and plasma TG accumulation in the T09-treated mice; this reduction may not be caused by decreased de novo FA synthesis, and it may not be secondary to alterations in cholesterol metabolism.

**Discussion**

Thus far, G0S2 has been best characterized in its antilipolytic role as an inhibitor of ATGL. Recent results obtained from G0S2-deficient mice have brought us closer to a proof of concept regarding the interplay between ATGL and G0S2 in the regulation of hepatic TG mobilization and adaptive energy response to fasting (20). However, the mechanism that regulates liver G0S2 expression is still elusive. In this context, the present study provides compelling evidence that hepatic G0S2, whose expression is responsive to an influx of adipose-derived FAs during fasting, is a direct target gene of LXRα. LXRα has been known to function critically in mediating fasting- and agonist-induced hepatic TG accumulation (32). In this regard, we demonstrate...
that the LXRα-G0S2 axis plays a pivotal role in the regulation of hepatic FA deposition in TGs under both conditions. Our results offer a new mechanism by which LXRα promotes liver steatosis that is separate from its established function to mediate de novo FA synthesis and reverse cholesterol trafficking.

Increased availability of adipose-derived FAs is generally believed to be the driving force for the fast-
ing induction of hepatic adaptive energy response. These FAs not only serve as substrates for hepatic β-oxidation and TG synthesis, but also play a critical role in the regulation of hepatic gene expression. In agreement with recent observations made in CGI-58-ATko mice (23), our study using AAKO mice similarly deficient in adipose lipolysis shows that hepatic G0S2 expression is causatively linked to adipose lipolysis upon fasting. The coculture experiments further demonstrate that the effect is the consequence of a direct induction of G0S2 gene transcription in hepatocytes by unsaturated FAs, including oleic acid and linoleic acid, that are released from lipolytically stimulated adipose tissue.
Using ChIP analysis on cross-linked chromatin isolated from liver tissues of fasted or agonist-treated mice, it became evident that LXRα but not LXRβ is abundantly enriched at the G0S2 promoter. Deletion analysis combined with a cell reporter assay confirms that the single DR4 motif within the putative LXRE of the G0S2 promoter is sufficient and required for activation by the LXRα/RXRα heterodimer. The slightly reduced binding affinity of LXRβ for the G0S2 LXRE as revealed by the EMSA assay may in part explain the lower level of LXRβ recruitment to the G0S2 promoter as observed from the ChIP assay. It is also possible that lower expression of LXRβ relative to that of LXRα contributes to the lower level of interaction of the G0S2 LXRE with LXRβ detected in vivo. In this regard, LXRα is known to be the predominant LXR isotype in liver.

The importance of LXRα for G0S2 expression is recognized in experiments using LXRα KO mice. In these mice, induction of hepatic G0S2 expression by fasting, acute stimulation of adipose lipolysis by CL, or LXR agonism by T09 was all abolished, correlating with alleviated steatosis in each case. While, in the fed state, LXRα are known to interact with insulin in the control of hepatic SREBP-1c and FA synthesis genes (38), the mechanisms that regulate LXRα during fasting are currently less well defined. In fasting liver, it is possible that the absence of insulin and the presence of unsaturated FAs alter the composition of cofactors and lipid mediators, thereby decreasing the binding LXRα to the SREBP-1c promoter while enhancing the specificity of LXRβ for the G0S2 promoter. The finding that unsaturated FAs derived from adipose lipolysis were sufficient to induce G0S2 expression in mouse primary hepatocytes in a LXRα-dependent manner is supportive of such a scenario. Since the RXR antagonist HX531 was able to block the effect of LXRα:RXRα on G0S2 promoter activity in vitro as well as the hepatic expression of G0S2 in mice during fasting or acute stimulation of adipose lipolysis, we speculate that the FA responsiveness of LXRα:RXRα is mediated via FA modification of RXR but not LXRβ. In this regard, RXR has long been recognized as an FA receptor that can be activated upon FA binding (39–43). Another observation made during this study is that hepatic LXRα mRNA levels in mice were increased at 16 hours of fasting. This is consistent with the findings obtained previously from fasted rats and chickens (44, 45). Given that LXRα expression in hepatocytes could be robustly induced by exogenously added FAs (45), it is possible that, during prolonged fasting, G0S2 expression in liver is activated by the influxed adipose-derived FAs at least in part through upregulation of LXRα expression.

A previous study has shown a differential expression of G0S2 in the livers of WT and PPARα KO mice (37). However, it seemed unconceivable that G0S2 would be a PPARα target, given the opposite roles of PPARα and G0S2 in regulating hepatic FA oxidation and TG deposition during fasting (20, 21, 46). The present study provides strong evidence that argues against a possible role of PPARα in mediating G0S2 expression. For example, PPARα activation by the synthetic ligand Wy14643 was insufficient to induce G0S2 expression in primary hepatocytes. Additionally, chemical antagonism of PPARα in mice had no effect on fasting-induced hepatic G0S2 expression, suggesting that PPARα is not required in vivo. Our findings are in agreement with the results from a previous study showing that PPARα was unable to activate G0S2 expression in a direct cell reporter assay using a G0S2 promoter construct (37). A separate observation that Wy14643 failed to increase hepatic G0S2 expression in CGI-58-ATko mice also is unsupportive of a sufficient role of PPARα in regulating G0S2 transcription in the absence of adipose lipolysis (23).

### Table 1. Plasma parameters in virus injected WT and LXRα KO mice after 16-hour fasting

<table>
<thead>
<tr>
<th>Parameter</th>
<th>WT (Ad-Null)</th>
<th>WT (Ad-G0S2)</th>
<th>LXRα KO (Ad-Null)</th>
<th>LXRα KO (Ad-G0S2)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glucose (mM)</td>
<td>2.37 ± 0.31</td>
<td>2.17 ± 0.24</td>
<td>2.69 ± 0.27</td>
<td>2.44 ± 0.29</td>
</tr>
<tr>
<td>TG (mM)</td>
<td>1.11 ± 0.23</td>
<td>1.35 ± 0.18</td>
<td>0.89 ± 0.14</td>
<td>1.07 ± 0.25</td>
</tr>
<tr>
<td>FFA (mM)</td>
<td>1.12 ± 0.19</td>
<td>1.19 ± 0.15</td>
<td>1.39 ± 0.21</td>
<td>1.41 ± 0.32</td>
</tr>
<tr>
<td>Total Cholesterol (mM)</td>
<td>1.95 ± 0.18</td>
<td>1.84 ± 0.31</td>
<td>1.77 ± 0.2</td>
<td>1.69 ± 0.17</td>
</tr>
<tr>
<td>HDL (mM)</td>
<td>1.24 ± 0.19</td>
<td>1.19 ± 0.20</td>
<td>1.16 ± 0.21</td>
<td>1.13 ± 0.22</td>
</tr>
<tr>
<td>LDL/vLDL (mM)</td>
<td>0.52 ± 0.14</td>
<td>0.47 ± 0.1</td>
<td>0.60 ± 0.07</td>
<td>0.54 ± 0.08</td>
</tr>
</tbody>
</table>

Eleven-week-old female WT and LXRα KO mice were injected with either Ad-null or Ad-G0S2 adenovirus and then fasted for 16 hours as shown in Figure 6. Blood was collected after fasting and plasma parameters were assayed. TG, triglyceride; FFA, free fatty acids; HDL, high density lipoprotein; LDL, low density lipoprotein; vLDL, very low density lipoprotein.
It is intriguing to speculate on the in vivo significance of hepatic G0S2 induction by LXRα. Existing evidence indicates that glucose and insulin signaling pathways are coordinated in carbohydrate feeding to synergistically activate LXRs in the liver (47–49). The induction of LXRs should lead to enhanced lipogenesis and cause an increase in newly generated FAs, providing a source of acyl residues to produce TGs through the glycerol phosphate pathway. The present study adds to this model by demonstrating that, by mediating G0S2 expression and thus attenuating ATGL-mediated lipolysis during physiological fasting, LXRα functions to promote the net deposition of influxed FAs in TGs, thereby limiting the amount of free FAs available for utilization in hepatocytes (Supplemental Figure 5). This could be especially relevant during the early stages of fasting when glycogen-derived glucose is the primary source of rapid energy output. Indeed, ablation of LXRα or G0S2 alone both led to delayed fasting-induced glycogen depletion in the liver, and hepatic overexpression of G0S2 in LXR KO mice was sufficient to accelerate glycogen breakdown while increasing TG accumulation. Moreover, we hypothesize that the increased hepatic TG storage capacity conferred by the activation of the LXRα-G0S2 axis serves as a defense mechanism against free FA-induced lipotoxicity when the rate of FA influx exceeds the rates for FAs to be utilized for β-oxidation and VLDL synthesis. Storing TGs in the liver when FAs are in excess could also favor long-term survival during times when food deprivation is extended and the adipose depot is exhausted.

Furthermore, our evidence demonstrates a required role for G0S2 in the hepatic TG accumulation induced by the pharmacological activation of LXRs. The further finding that loss of G0S2 affected TG content but not lipogenic gene expression in response to T09 suggests that, without G0S2, increased de novo FA synthesis may be insufficient to drive TG accumulation. More importantly, synthetic LXR agonists are well documented as putative pharmacological agents for hypercholesterolemia and atherosclerosis (50–56). The LXR agonism leads to activation of the reverse pathway for cholesterol transport and both biliary and fecal cholesterol excretion. Despite their antiatherogenic benefits, the LXR agonists such as T09 also cause undesirable effects, including hypertriglyceridemia and hepatic steatosis (33, 50–56). In the present study, we demonstrate that, in the absence of G0S2, T09 is able to retain its positive effect on cholesterol/reverse cholesterol trafficking, while rendered incapable of inducing the negative side effects of increasing plasma TG and causing hepatic steatosis. Thus, our observations may open a new therapeutic strategy based on the modulation of hepatic G0S2 to alleviate hepatic steatosis and hypertriglyceridemia in response to LXR agonism.

Methods

Supplemental Methods are available online with this article.

Animal experiments. Mice lacking ATGL were generated previously by targeted homologous recombination as described (57). Heterozygous ATGL+/− mice were used to generate the whole-body ATGL KO. These mice were subsequently used for adipose tissue excision and explant culture. Adipose-specific ATGL KO mice (AAKO) were produced as previously described (36). For experimental analysis, male AAKO mice and age-matched WT littermates at 24 weeks of age were used. LXR KO mice were purchased from The Jackson Laboratory along with age-matched WT mice on C57BL6/J background. Unless otherwise noted, female mice at 10 weeks of age were used for experimental analysis. G0S2 KO mice were produced as previously reported (20). For experimental analysis, female WT and G0S2 KO littermates 12 weeks of age were used. All mice were given free access to water and were fed a standard chow diet (TestDiet, number 5001).

Agonist and antagonist injections. LXRα agonist T09 and GW3965, LXRα antagonist GSK2033, RXRα antagonist HX-531, PPARα agonist Wy14643, and PPARα antagonist GW6471 were suspended in PBS containing 0.5% Tween-80, which was also used as the control vehicle. Mice were injected i.p. with either drug or vehicle at a dose of 20 mg/kg/day (T09 and GSK2033) or 10 mg/kg/day (HX-531) for 3 days.

Adipose tissue explant and FA profiling. For adipose explant culture, gonadal adipose tissue was isolated from WT and ATGL KO mice. The fat pads were trimmed and placed in 12-well tissue culture dishes. Media containing high-glucose DMEM with 2% FA-free BSA without serum was used. To induce adipose lipolysis ex vivo, the fat pads were treated with 10 μM CL for 2 hours. After treatment, the media was collected and used for primary hepatocyte coculture experiments described below. For adipose lipolysis FA profiling, gonadal adipose tissue was again isolated from WT mice and explant cultured. Stimulation of lipolysis was achieved by treatment with 10 μM CL for 2 hours. Media was subsequently collected and snap frozen in LN₂. FA species profiling was accomplished by HPLC analysis completed by the Vanderbilt Hormone Assay Core facility (Nashville, Tennessee, USA).
Primary hepatocyte isolation and coculture treatment. Mouse primary hepatocytes were isolated from WT mice as described (58). Hepatocytes were cultured on sterile collagen-coated tissue culture dishes for 24 hours prior to coculture with adipose tissue explant media (conditioned media). Media was collected from adipose explants, as described above. Hepatocytes were then exposed to the conditioned media for a period of 8 hours prior to lysis. Hepatocytes exposed to individual BSA-conjugated FAs were treated for 8 hours at varying doses, as described in the figure legends. Individual FA treatment concentration was consistent with the molar amount released during stimulation of adipose lipolysis by CL in explant culture.

ChIP. ChIP assays for LXRα and LXRβ were performed on fresh liver tissue isolated from WT mice in the fed or 16-hours fasted state, or injected with vehicle or T09, as described above. Mice were sacrificed by cervical dislocation, and the liver was rapidly excised, minced, and placed in 1% formaldehyde solution and fixed for 15 minutes at room temperature. To stop fixation, glycine was added to a final concentration of 0.125 M, and samples were mixed thoroughly. The tissue pellet was aggregated by centrifugation and washed with cold PBS twice. The fixed tissue was then homogenized in a dounce homogenizer in lysis buffer containing 10 mM Tris-HCl (pH 8), 10 mM NaCl, 0.2% NP-40, and Complete, Mini Protease Inhibitor Cocktail (all reagents from Sigma-Aldrich). Nuclei were then pelleted by centrifugation at 1,500 g for 15 minutes at 4°C. The nuclear pellet was resuspended and homogenized by dounce in a nuclear lysis buffer containing 50 mM Tris-HCl (pH 8), 10 mM EDTA, 1% SDS, and protease inhibitors. Samples were then sonicated on ice using a VirSonic digital probe sonifier for 10 cycles at 15 seconds at a power setting of 25%. Postsonication shearing controls were conducted to ensure sonication of chromatin to approximately 300–500 bp. For IP, 100 μg total chromatin from each sample was diluted to 1 ml in dilution buffer consisting of 1% triton X-100, 150 mM NaCl, 2 mM EDTA, 20 mM Tris-HCl (pH 8), and protease inhibitors. ChIP-grade antibodies against LXRα and LXRβ were purchased from Santa Cruz Biotechnology Inc. Normal rabbit IgG was used as an IP control (Abcam). Primary antibodies (5 μg) were added to the diluted chromatin and incubated overnight at 4°C with rotation. Protein A/G beads (50 μl) purchased from Santa Cruz Biotechnology Inc. were then added to each IP and were incubated with rotation at 4°C for 1 hour. Beads were then washed 4 times in a buffer consisting of 0.1% SDS in dilution buffer. Beads were then washed 2 times in standard TE buffer with protease inhibitors. Beads were resuspended in 120 μl of elution buffer containing 1% SDS and 100 mM NaHCO₃. To elute bound chromatin, the beads were slowly vortexed for 15 minutes at 30°C. After elution, beads were centrifuged, and the supernatant was collected. NaCl was added, and samples were incubated overnight at 65°C to reverse cross-linking. RNase A (10 mg/ml) and proteinase K (20 mg/ml) were added and incubated with shaking at 45°C for 1 hour (Invitrogen). The DNA was purified by phenol/chloroform/isoamyl alcohol extraction and resuspended in ultrapure water. Purified chromatin was then used for quantitative PCR (qPCR) analysis. Primers specific for the G0S2 –2 kb DR4/flanking non-LXR binding regions of the G0S2 promoter were purchased from Santa Cruz Biotechnology Inc. Normal rabbit IgG was used as an IP control (Abcam). Primary antibodies (5 μg) were added to the diluted chromatin and incubated overnight at 4°C with rotation. Protein A/G beads (50 μl) purchased from Santa Cruz Biotechnology Inc. were then added to each IP and were incubated with rotation at 4°C for 1 hour. Beads were then washed 4 times in a buffer consisting of 0.1% SDS in dilution buffer. Beads were then washed 2 times in standard TE buffer with protease inhibitors. Beads were resuspended in 120 μl of elution buffer containing 1% SDS and 100 mM NaHCO₃. To elute bound chromatin, the beads were slowly vortexed for 15 minutes at 30°C. After elution, beads were centrifuged, and the supernatant was collected. NaCl was added, and samples were incubated overnight at 65°C to reverse cross-linking. RNase A (10 mg/ml) and proteinase K (20 mg/ml) were added and incubated with shaking at 45°C for 1 hour (Invitrogen). The DNA was then purified by phenol/chloroform/isoamyl alcohol extraction and resuspended in ultrapure water. Purified chromatin was then used for quantitative PCR (qPCR) analysis. Primers specific for the G0S2 –2 kb DR4/LXRE were as follows FWD: 5′– AGAATTAAGCCCAAGTCAGGATCC – 3′ and REV: 5′– TTCAAAAGTGAAAGGTTCACACTTGAG – 3′. Primers for the 5′ and 3′ flanking non-LXR binding regions of the G0S2 promoter were designed as follows: 5′ flanking FWD: 5′– GCAATTTGTGTGTGCGTGTG – 3′ and REV: 5′– CATATCTGTAATTTCCAGCAA – 3′ and 3′ flanking FWD: 5′– AAAGAGCGAGCCTGAGGA – 3′ and REV: 5′– GGCTGCTGACTAGGGGAACT – 3′. Positive control LXRE primers were from murine SREBP-1c and ChREBP as was a nonspecific negative control primer reported previously (26, 59). qPCR data from ChIP samples is represented as fold enrichment between treatment conditions normalized to the IgG control samples.

Gel shift assays. LXRα, LXRβ, and RXRα were in vitro translated using the TNT SP6 cell-free transcription/translation system (Promega) according to the manufacturer’s protocol. The LightShift EMSA kit (Thermo Fisher Scientific) was used for the binding reactions according to the manufacturer’s instructions. Duplexed 5′ biotin labeled probes for SREBP-1c (+), control LXRE, G0S2 LXRE, and nonspecific, and unlabeled competitor oligos were synthesized by Integrated DNA Technologies (Supplemental Table 2). Reactions were subsequently resolved on a 5% nondenaturing PAGE gel (in house) and transferred to positively charged nylon membranes. The LightShift DNA detection module (Thermo Fisher Scientific) was used for chemiluminescent analysis.

PCR cloning of DNA and site-directed mutagenesis. The pGL4 luciferase reported plasmids were constructed from the 3 kb proximal promoter sequence of murine G0S2. Genomic DNA was extracted from mouse liver using the AllPrep Genomic DNA purification/extraction kit according to the manufacturer’s instructions (Qiagen). Purified mouse genomic DNA was used as a template to amplify the 3 kb promoter region 10 bp upstream of the G0S2 start codon using the following primers; FWD: 5′– TATTTGTTCATAATCATTCAACAAA – 3′ and REV: 5′– TCTGCAGGCCCAGCCACCACTGACCC – 3′. For cloning into pGL4
vector (Promega) to produce pGL4/G0S2 (−3,010 to −10), NheI and HindIII restriction sites were engineered onto the 5′ ends of the FWD and REV primers, respectively. To construct pGL4/G0S2 (−2,283 to −1783), the 3 kb promoter fragment was used as a template to amplify the shorter 500 bp sequence using the following primers; FWD: 5′ − TGCCCTCCGTCAAGGACACATCA − 3′ and REV: 5′ − AAGATTGCATCATGTGACCTTTGCAA − 3′. Again, NheI and HindIII sites were added as described for ligation into empty pGL4 plasmid. Site-directed mutagenesis was used as described above on pGL4/G0S2 (−2,283 to −1783) to produce the DR4/LXRE deficient pGL4/G0S2 (−2,283 ΔDR4 −1,783). Primers for the mutagenesis reaction were as follows; FWD: 5′ − AGAATAATCTCTGATGCACTTTATGTAT − 3′ and REV: 5′ − ATACATAAGTGATCAGATGAGGATTATTCT − 3′. All plasmids were validated by restriction enzyme digestion and sequencing.

Luciferase reporter assays. For analyzing G0S2 promoter activity, HeLa cells were cotransfected with empty pGL4 or specific G0S2 pGL4 reporter plasmids, LXRα and RXRα. Plasmid constructs for LXRα and RXRα were purchased from Addgene. For directly assaying the impact of FA on LXRα, HepG2 cells were transfected with the LXRα-LBD/Gal4-DBD fusion and MH100-Luc plasmids (gifts from Changcheng Zhou, University of Kentucky, Lexington, Kentucky, USA). Following transfection, cells were treated in the presence or absence of 10 μM T09, 750 μM linoleic acid, or 500 μM oleic acid. Luciferase activity was then assayed using the Luciferase Assay System from Promega according to the manufacturer’s instructions.

Statistics. Values are expressed as mean ± SD. Statistical significance was evaluated by 2-tailed unpaired Student’s t test. Differences were considered significant at P < 0.05. Quantitative data is presented as either Dot plots or Box-and-Whisker plots as described in each figure legend.

Study approval. All animal experiments were done in accordance with protocols approved by the Mayo Clinic Institutional Animal Care and Use Committee.

Author contributions
Conceptualization was done by BLH and JL; methodology was completed by BLH, XZ, and JL; investigation was performed by BLH, XZ, AMS, GS, and EEU; EEU and RZ provided resources; writing and editing was done by BLH, RZ, and JL; BLH and JL provided supervision; review and discussions were provided by EEU and RZ; and funding acquisition was provided by JL and EEU.

Acknowledgments
We would like to thank the Vanderbilt Hormone Assay Core facility for their expertise in lipid/FA profiling. We would also like to thank Changcheng Zhou (University of Kentucky) and Xitao Xie (Arizona State University) for critical discussions. This work was supported by research grants from the NIH (DK089178 and DK109096) to JL, NIH (DK090166) to EEU, as well as predoctoral funding to BLH from the Mayo Foundation for Medical Education & Research.

Address correspondence to: Jun Liu, MCCRB 3-054, 13400 E. Shea Boulevard, Scottsdale, Arizona 85259, USA. Phone: 480.301.6745; E-mail: liu.jun@mayo.edu.

BLH’s present address is: Department of Immunology, St. Jude Children’s Research Hospital, Memphis, Tennessee, USA.


